Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY).
Aniruddha Kishandutt AgarwalSridharan SudharshanPadmamalini MahendradasKalpana BabuPratik ShenoyMohit DograReema BansalManisha AgarwalJyotirmay BiswasS BalamuruganRupesh AgrawalVishali GuptaPublished in: The British journal of ophthalmology (2020)
During the ongoing COVID-19 pandemic, uveitis specialists may tend to reduce the ongoing systemic IMT, or prefer less aggressive treatment strategies for NIU. These subjects may be at high risk of relapse of uveitis.